Clinical Trial Update: Role of Hemostatic Powder (Endo-clotTM) in Prevention of Bleeding Within High Risk Patients After ESD [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated EndoClot hemostatic powder to prevent post-endoscopic submucosal dissection bleeding in high-risk patients; the study status is comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iatrogenic Ulcer After Endoscopic Submucosal Dissection

Drugs mentioned

• EndoClot

Snippet

Sponsor: Yonsei University | Conditions: Iatrogenic Ulcer After ESD | Phase 3 | Status: COMPLETED